Intima Bioscience

Executive Summary

Intima Bioscience is a clinical-stage biotechnology company pioneering a novel small molecule checkpoint inhibitor targeting CISH, an intracellular immune checkpoint that suppresses T cell and NK cell activity. By drugging this previously undruggable target, Intima aims to develop next-generation cancer immunotherapies with improved efficacy and tolerability compared to existing checkpoint inhibitors. The company's lead program is in Phase 1 clinical trials, and its principal investigator, Dr. Emil Lou, was recently recognized on the 2026 TIME100 Health list, underscoring the scientific credibility and potential impact of the platform. Based in London, UK, Intima is positioned to address significant unmet needs in oncology by reactivating anti-tumor immunity through a distinct mechanism.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and efficacy data readout60% success
• Q2 2026Presentation at major medical conference (e.g., ASCO or SITC)70% success
• TBDAnnouncement of strategic partnership or licensing deal40% success